An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Bristol-Myers Squibb
Study ID
NCT02581631
Phase
PHASE1/PHASE2
Status
Completed

Conditions

  • Non-Hodgkin's Disease

Eligibility Criteria

Sex
ALL
Age
15 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab — BIOLOGICAL
  • Brentuximab Vedotin — DRUG

Study Details

The purpose of this study is to determine whether Nivolumab, in combination with brentuximab vedotin, is safe and effective in patients with certain subtypes of non-Hodgkin's lymphomas with CD30 expression that have not responded to treatment or have come back. The subtypes we are studying are Diffuse Large B-Cell Lymphoma (DLBCL), Peripheral T-Cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL), Primary Mediastinal Large B-Cell Lymphoma (PMBL) and Mediastinal Gray Zone Lymphoma (MGZL).

Key Dates

Start date
Feb 11, 2016
Status verified
Feb 2023
Primary completion
Jan 16, 2020
Completion
Feb 7, 2022

Study Design

Enrollment
145 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Nivolumab+Brentuximab Vedotin
    Nivolumab+Brentuximab Vedotin dose as specified

Primary Outcome Measure

Safety Analysis - Number of Participants With Dose Limiting Toxicities (DLT) in the DLT Evaluation Phase [ Time Frame: From first dose of treatment to 6 weeks after first dose ]

Locations (16)

FacilityCityStateZIPSite coordinators
Local Institution - 0017BirminghamAlabama35294-3300-
University Of Miami Sylvester Comprehensive Cancer CenterMiamiFlorida33136-
Local Institution - 0012TampaFlorida33612-
Winship Cancer Institute.AtlantaGeorgia30322-
University Of ChicagoChicagoIllinois60637-
Mayo ClinicRochesterMinnesota55905-
Washington University School Of MedicineSt LouisMissouri63110-
Local Institution - 0003New YorkNew York10021-
Local Institution - 0010New YorkNew York10029-
University Of RochesterRochesterNew York14642-
Levine Cancer InstituteCharlotteNorth Carolina28204-
The Ohio State University Comprehensive Cancer CenterColumbusOhio43210-
Stephenson Cancer CenterOklahoma CityOklahoma73104-
Providence Portland Medical CenterPortlandOregon97213-
Bon Secours-St Francis HospGreenvilleSouth Carolina29607-
University of Washington - Seattle Cancer Care AllianceSeattleWashington98109-1023-

Find similar trials in Birmingham, AL